Login to Your Account



Evotec Gets $15M Up Front in Bayer Endometriosis Pact


Monday, October 1, 2012
Evotec AG is pocketing €12 million (US$15.5 million) up front and could receive up to €580 million more in preclinical, clinical and commercial milestones from a drug discovery alliance focused on endometriosis with Bayer Pharma AG.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription